欧剑锋 王蕾 潘耀柱 张姝婷 白海.嵌合抗原受体修饰T 细胞免疫治疗肿瘤的研究进展[J].现代生物医学进展英文版,2016,16(2):373-376. |
嵌合抗原受体修饰T 细胞免疫治疗肿瘤的研究进展 |
Advances in Cancer Immunotherapy Adopting Chimeric AntigenReceptor-modified T Lymphocytes |
|
DOI: |
中文关键词: 嵌合抗原受体 T细胞 免疫治疗 肿瘤 |
英文关键词: Chimeric antigen receptor T lymphocytes Immunotherapy Tumor |
基金项目:国家自然科学基金项目(81372132) |
|
Hits: 821 |
Download times: 0 |
中文摘要: |
以嵌合抗原受体修饰T 细胞(chimeric antigen receptor modified -T lymphocytes, CAR-T)为基础的过继细胞免疫治疗近年来
成为治疗恶性肿瘤的一种新模式。CAR-T细胞赋予T细胞靶向杀伤活性,并可克服肿瘤免疫抑制和打破宿主免疫耐受。尽管目前
CAR-T 的临床应用还存在诸如脱靶效应、细胞因子风暴、插入突变和移植物抗宿主病样损伤等许多问题,但我们相信随着对
CAR-T细胞的深入研究及推广应用将会大幅度提高肿瘤的临床治疗效果。本文就CAR-T细胞应用于肿瘤免疫治疗的前生、今世
和将来作一综述。 |
英文摘要: |
Chimeric antigen receptor modified-T lymphocytes (CAR-T) based adoptive antitumor immunotherapy has became an
emerging therapeutic modality for malignant tumor in recent years. CAR-T cells give the targeted killing activity of T lymphocytes,
which they can resist the tumor immunosuppression and break the host immune tolerance. Although there still exist many problems for
CAR-T on the clinical application such as off-target effects, cytokine storm, insertion mutagenesis, graft versus host disease-like damage
and many other problems, but we believe that with the in-depth study of the CAR-T cells and application will greatly improve the
therapeutic effects of tumor. We summarized the past history, present status and future prospect of tumor immunotherapy adopting
CAR-T in this review. |
View Full Text
View/Add Comment Download reader |
Close |